Synapse - MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone

MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone Meeting Abstract

Authors:	Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; Sams, A.; Diab, V.; Chung, D. J.; Scordo, M.; Lahoud, O. B.; Landau, H. J.; Arcila, M. E.; Giralt, S.; Ho, C.; Roshal, M.; Devlin, S. M.; Dogan, A.; Landgren, O.
Abstract Title:	MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
Meeting Title:	60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	132
Issue:	Suppl. 1
Meeting Dates:	2018 Dec 1-4
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2018-11-29
Language:	English
ACCESSION:	WOS:000454837605311
PROVIDER:	wos
DOI:	10.1182/blood-2018-99-117120
Notes:	Meeting Abstract: 1983 -- Source: Wos